The TZM-bl assay measures antibody-mediated neutralization of HIV-1 as a function of
reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a …

The development of an effective vaccine has been hindered by the enormous diversity of
human immunodeficiency virus‐1 (HIV‐1) and its ability to escape a myriad of host immune …

The development of stabilized recombinant HIV envelope trimers that mimic the virion
surface molecule has increased enthusiasm for a neutralizing antibody (nAb)-based HIV …

Background The development of a safe and effective vaccine against the human
immunodeficiency virus type 1 (HIV-1) is critical to pandemic control. Methods In a …

Antibodies that neutralize diverse strains of HIV-1 develop in∼ 20% of HIV-1-infected
individuals, and isolation and structural characterization of these antibodies are revealing …

Identification of full-length transmitted HIV-1 genomes could be instrumental in HIV-1
pathogenesis, microbicide, and vaccine research by enabling the direct analysis of those …

The restricted neutralization breadth of vaccine-elicited antibodies is a major limitation of
current human immunodeficiency virus-1 (HIV-1) candidate vaccines. In order to permit the …

Summary VRC-HIVMAB060-00-AB (VRC01) is a broadly neutralizing HIV-1 monoclonal
antibody (mAb) isolated from the B cells of an HIV-infected patient. It is directed against the …

Standardized assessments of HIV-1 vaccine-elicited neutralizing antibody responses are
complicated by the genetic and antigenic variability of the viral envelope glycoproteins …

Induction of broadly cross-reactive neutralizing antibodies is a high priority for AIDS vaccine
development but one that has proven difficult to be achieved. While most immunogens …